Zusammenfassung
Östrogenhaltige Kontrazeptiva und eine Hormonersatztherapie werden weltweit von Millionen Frauen genutzt. Obwohl die Verträglichkeit generell sehr gut ist, besteht ein Risiko venöser und arterieller Thromboembolien. Im vorliegenden Beitrag werden nicht nur häufige Thrombophilien beschrieben, sondern Risikofaktoren für Thrombosen und Lungenembolien erklärt. Das thromboembolische Risiko unter verschiedenen Präparaten wird diskutiert und Risikofaktoren unter einer entsprechenden Therapie beschrieben. Zudem werden Handlungsanweisungen für die tägliche Praxis präsentiert.
Abstract
Combined oral contraceptives (COC) and hormone replacement treatment are used by millions of women worldwide due to the reliable contraception and other health benefits they offer. Although side effects are few, the treatment puts patients at risk for venous and atrial thromboembolism. The following article describes common thrombophilic situations and risk factors for deep vein thrombosis and pulmonary embolism. The thromboembolic risk of patients treated with different types of estrogen-containing drugs is summarized and related risk factors discussed. Guidance for use in clinical practice is also provided.
Literatur
Angelillo-Scherrer A, Nagler M (2016) Thrombophilieabklarung. Ther Umsch 73(10):626–634
Nygaard K, Brown G (1937) Essential thrombophilia, report of five cases. Arch Intern Med 59:82–106
Egeberg O (1965) Inherited Antithrombin deficiency causing Thrombophilia. Thromb Diath Haemorrh 13:516–530
Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C (1981) Deficiency of protein C in congenital thrombotic disease. J Clin Invest 68(5):1370–1373
Comp PC, Esmon CT (1984) Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 311(24):1525–1528
Dahlback B, Hildebrand B (1994) Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 91(4):1396–1400
Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88(10):3698–3703
Garcia D, Erkan D (2018) Diagnosis and management of the Antiphospholipid syndrome. N Engl J Med 378(21):2010–2021
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, De Groot PG, Koike T, Meroni PL et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295–306
Gando S, Levi M, Toh CH (2016) Disseminated intravascular coagulation. Nat Rev Dis Primers 2:16037
Bushman JE, Palmieri D, Whinna HC, Church FC (2000) Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia. Leuk Res 24(7):559–565
Kyrle PA, Rosendaal FR, Eichinger S (2010) Risk assessment for recurrent venous thrombosis. Lancet 376(9757):2032–2039
Heit JA (2015) Epidemiology of venous thromboembolism. Nat Rev Cardiol 12(8):464–474
Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158(6):585–593
Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F et al (2012) Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e419S–e496S
Angelini D, Khorana AA (2017) Risk assessment scores for cancer-associated venous Thromboembolic disease. Semin Thromb Hemost 43(5):469–478
Iorio A, Kearon C, Filippucci E, Marcucci M, Macura A, Pengo V, Siragusa S, Palareti G (2010) Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med 170(19):1710–1716
Nagler M, Ten Cate H, Prins MH, Ten Cate-Hoek AJ (2018) Risk factors for recurrence in deep vein thrombosis patients following a tailored anticoagulant treatment incorporating residual vein obstruction. Res Pract Thromb Haemost 2(2):299–309
Roach RE, Lijfering WM, Tait RC, Baglin T, Kyrle PA, Cannegieter SC, Rosendaal FR (2015) Sex difference in the risk of recurrent venous thrombosis: a detailed analysis in four European cohorts. J Thromb Haemost 13(10):1815–1822
Eichinger S, Weltermann A, Minar E, Stain M, Schonauer V, Schneider B, Kyrle PA (2004) Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch Intern Med 164(1):92–96
Eichinger S, Minar E, Bialonczyk C, Hirschl M, Quehenberger P, Schneider B, Weltermann A, Wagner O, Kyrle PA (2003) D‑dimer levels and risk of recurrent venous thromboembolism. JAMA 290(8):1071–1074
Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, Pengo V, Ghirarduzzi A, Pattacini C, Testa S et al (2006) D‑dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 355(17):1780–1789
Ensor J, Riley RD, Moore D, Snell KI, Bayliss S, Fitzmaurice D (2016) Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE. BMJ Open 6(5):e11190
FSRH Guideline (2019) FSRH Guideline (January 2019) Combined Hormonal Contraception (Revision due by January 2024). BMJ Sex Reprod Health 45(Suppl 1):1–93
Lidegaard O, Lokkegaard E, Svendsen AL, Agger C (2009) Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 339:b2890
Lekovic D, Miljic P, Dmitrovic A, Thachil J (2017) How do you decide on hormone replacement therapy in women with risk of venous thromboembolism? Blood Rev 31(3):151–157
van Vlijmen EF, Wiewel-Verschueren S, Monster TB, Meijer K (2016) Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 14(7):1393–1403
Garcia D, Akl EA, Carr R, Kearon C (2013) Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood 122(5):817–824
Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO (2012) VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e691S–e736S
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
M. Pollak und M. Nagler geben an, dass kein Interessenkonflikt besteht.
Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Additional information
Redaktion
B. Imthurn, Zürich
B. Toth, Innsbruck
Rights and permissions
About this article
Cite this article
Pollak, M., Nagler, M. Thrombophilieabklärung im Hinblick auf östrogenhaltige Kontrazeptiva und Hormonersatztherapie. Gynäkologische Endokrinologie 17, 139–147 (2019). https://doi.org/10.1007/s10304-019-0262-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10304-019-0262-y
Schlüsselwörter
- Epidemiologie der venösen Thromboembolie
- Prävention der venösen Thromboembolie
- Unerwünschte Wirkungen kombinierter oraler Kontrazeptiva
- Unerwünschte Wirkungen der Östrogenersatztherapie
- Thrombophilieabklärung